Pénélope Desroys du Roure

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Smoking Cessation

Prostate Cancer

Top Venues

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Pénélope Desroys du Roure, Lajoie Laurie, Aude Mallavialle, Lindsay B Alcaraz, Hanane Mansouri, Lise Fenou, Véronique Garambois, Lucie Rubio, Timothée David, Loïs Coënon, Florence Boissière, Marie-Christine Chateau, Giang Ngo, Marta Jarlier, Martín Villalba, Pierre Martineau, Valérie Laurent-Matha, Pascal Roger, Séverine Guiu, Thierry Chardès, Laurent Gros, Emmanuelle Liaudet-Coopman
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for immunotherapy of cancer 12 (1) (2024)
Pénélope Desroys du Roure, Lajoie Laurie, Aude Mallavialle, Lindsay B Alcaraz, Hanane Mansouri, Lise Fenou, Véronique Garambois, Lucie Rubio, Timothée David, Loïs Coënon, Florence Boissière, Marie-Christine Chateau, Giang Ngo, Marta Jarlier, Martín Villalba, Pierre Martineau, Valérie Laurent-Matha, Pascal Roger, Séverine Guiu, Thierry Chardès, Laurent Gros, Emmanuelle Liaudet-Coopman
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for immunotherapy of cancer 12 (1) (2024)
Pénélope Desroys du Roure, Lajoie Laurie, Aude Mallavialle, Lindsay B Alcaraz, Hanane Mansouri, Lise Fenou, Véronique Garambois, Lucie Rubio, Timothée David, Loïs Coënon, Florence Boissière, Marie-Christine Chateau, Giang Ngo, Marta Jarlier, Martín Villalba, Pierre Martineau, Valérie Laurent-Matha, Pascal Roger, Séverine Guiu, Thierry Chardès, Laurent Gros, Emmanuelle Liaudet-Coopman
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for immunotherapy of cancer 12 (1) (2024)
Pénélope Desroys du Roure, Lajoie Laurie, Aude Mallavialle, Lindsay B Alcaraz, Hanane Mansouri, Lise Fenou, Véronique Garambois, Lucie Rubio, Timothée David, Loïs Coënon, Florence Boissière, Marie-Christine Chateau, Giang Ngo, Marta Jarlier, Martín Villalba, Pierre Martineau, Valérie Laurent-Matha, Pascal Roger, Séverine Guiu, Thierry Chardès, Laurent Gros, Emmanuelle Liaudet-Coopman
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. Journal for immunotherapy of cancer 12 (1) (2024)